|
1
|
Sinha S, Tong WY, Williamson NH, McInnes SJP, Puttick S, Cifuentes-Rius A, Bhardwaj R, Plush SE, Voelcker NH. Novel Gd-Loaded Silicon Nanohybrid: A Potential Epidermal Growth Factor Receptor Expressing Cancer Cell Targeting Magnetic Resonance Imaging Contrast Agent. ACS APPLIED MATERIALS & INTERFACES 2017; 9:42601-42611. [PMID: 29154535 DOI: 10.1021/acsami.7b14538] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Continuing our research efforts in developing mesoporous silicon nanoparticle-based biomaterials for cancer therapy, we employed here porous silicon nanoparticles as a nanocarrier to deliver contrast agents to diseased cells. Nanoconfinement of small molecule Gd-chelates (L1-Gd) enhanced the T1 contrast dramatically compared to distinct Gd-chelate (L1-Gd) by virtue of its slow tumbling rate, increased number of bound water molecules, and their occupancy time. The newly synthesized Gd-chelate (L1-Gd) was covalently grafted on silicon nanostructures and conjugated to an antibody specific for epidermal growth factor receptor (EGFR) via a hydrazone linkage. The salient feature of this nanosized contrast agent is the capability of EGFR targeted delivery to cancer cells. Mesoporous silicon nanoparticles were chosen as the nanocarrier because of their high porosity, high surface area, and excellent biodegradability. This type of nanosized contrast agent also performs well in high magnetic fields.
Collapse
Affiliation(s)
- Sougata Sinha
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
| | - Wing Yin Tong
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Nathan H Williamson
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
| | - Steven J P McInnes
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
| | - Simon Puttick
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland , St. Lucia, Brisbane, Queensland 4072, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) , Clayton, Victoria Australia
| | - Anna Cifuentes-Rius
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Richa Bhardwaj
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
| | - Sally E Plush
- Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia , Adelaide, South Australia 5000, Australia
| | - Nicolas H Voelcker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia , Mawson Lakes, South Australia 5095, Australia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville, Victoria 3052, Australia
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) , Clayton, Victoria Australia
- Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility , Clayton, Victoria 3168, Australia
- Monash Institute of Medical Engineering, Monash University , Clayton, Victoria 3800, Australia
| |
Collapse
|
|
2
|
Xu H, Liu P, Mi X, Xu L, Yang Y. Potent and regularizable crosslinking of ultrafine fibrous protein scaffolds for tissue engineering using a cytocompatible disaccharide derivative. J Mater Chem B 2015; 3:3609-3616. [DOI: 10.1039/c4tb02100b] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A sucrose derived crosslinker enhanced the water stability of ultrafine fibrous protein scaffolds efficiently and showed biocompatibility similar to citric acid.
Collapse
Affiliation(s)
- Helan Xu
- Department of Textiles
- Merchandising and Fashion Design
- 234, HECO Building
- University of Nebraska-Lincoln
- Lincoln
| | - Peng Liu
- Key Laboratory of Science and Technology of Eco-Textiles
- Ministry of Education
- Donghua University
- China
| | - Xiang Mi
- Key Laboratory of Science and Technology of Eco-Textiles
- Ministry of Education
- Donghua University
- China
| | - Lan Xu
- Department of Agronomy and Horticulture
- University of Nebraska-Lincoln
- Lincoln
- USA
| | - Yiqi Yang
- Department of Textiles
- Merchandising and Fashion Design
- 234, HECO Building
- University of Nebraska-Lincoln
- Lincoln
| |
Collapse
|
|
3
|
Zuberbühler K, Casi G, Bernardes GJL, Neri D. Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem Commun (Camb) 2012; 48:7100-2. [PMID: 22684082 DOI: 10.1039/c2cc32412a] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We describe a method that enables specific and efficient conjugation of hydrazide-moieties to an IgG targeting the tumor neovasculature. The resulting chemically defined, homogeneous hydrazone-linked IgG conjugates remain immunoreactive and have a half-life of approximately 18 hours at physiological pH and temperature suitable for localized delivery of toxic drugs.
Collapse
Affiliation(s)
- Kathrin Zuberbühler
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang-Pauli Str. 10, 8093 Zürich, Switzerland
| | | | | | | |
Collapse
|